Skip to content

Deepak Cyril D’souza

11 papers in the library · 807 citations · publishing 2004-2025

Papers

Sort Most recent Most cited

Psilocybin’s Effects on Headache Frequency are Not Related to Acute Psychedelic Effects or Measures of Mental Health: Secondary Analysis of Clinical Trials in Migraine and Cluster Headache (P7-12.001)

Neurology April 7, 2025 Emmanuelle A. D. Schindler, Christopher Gottschalk, Deepak Cyril D’souza 2 citations

To examine the relationship of acute psychedelic effects and measures of mental health with headache frequency in clinical trials of psilocybin in migraine and cluster headache.

DOI: 10.1212/wnl.0000000000210945 (opens in new tab) Psilocybin Migraine Cluster headache Clinical trial +2

Addressing blinding in classic psychedelic studies with innovative active placebos.

The International Journal of Neuropsychopharmacology April 1, 2025 Jacob S. Aday, Otto Simonsson, Emmanuelle A. D. Schindler et al. 25 citations

Classic psychedelics have shown promise in the treatment of various neuropsychiatric disorders. However, weak blinding integrity has been argued to limit the interpretability of therapeutic effects observed in psychedelic clinical trials, highlighting the need to explore alternative active placebos. Here, we aimed to describe the drawbacks of current placebo conditions used in classic...

DOI: 10.1093/ijnp/pyaf023 (opens in new tab) Full text (opens in new tab) Psychedelic research Clinical trials methodology Placebo effect Pharmaceutical testing +1

Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging February 1, 2024 Friederike Holze, Nirmal Singh, Matthias E. Liechti et al. 50 citations

Psychedelic compounds, including psilocybin, LSD (lysergic acid diethylamide), DMT (N,N -dimethyltryptamine), and 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), all of which are serotonin 2A receptor agonists, are being investigated as potential treatments. This review aims to summarize the current clinical research on these 4 compounds and mescaline to guide future research. Their mechanism(s)...

Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms

Journal of Psychopharmacology June 30, 2023 Jordan Sloshower, Hamideh Safi-Aghdam, Surbhi Pathania et al. 47 citations

Background: Evidence suggests that serotonergic psychedelics (e.g. psilocybin), have rapid-acting and long-lasting antidepressant effects after a single dose. However, the mechanism underlying these effects remain unclear. One proposed mechanism is that these drugs promote neuroplasticity. However, this has not been conclusively demonstrated in humans. Aims: We hypothesized that relative to...

Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial

Journal of Psychopharmacology March 20, 2023 Jordan Sloshower, Hamideh Safi-Aghdam, Surbhi Pathania et al. 153 citations

Background: Several early phase studies have demonstrated that psilocybin-assisted therapy has rapid-acting and persisting antidepressant effects from just one or two doses. However, methodological limitations (e.g., placebo-control, blinding) limit interpretability of the existing literature. Methods: In an exploratory placebo-controlled, within-subject, fixed-order study, individuals with...

Exploratory investigation of a patient‐informed low‐dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double‐blind, placebo‐controlled trial

Headache: The Journal of Head and Face Pain November 1, 2022 Christina Luddy, Yutong Zhu, Hayley Lindsey et al. 75 citations

Abstract Objective Using a patient‐informed regimen, we conducted an exploratory randomized, double‐blind, placebo‐controlled study to systematically investigate the effects of psilocybin in cluster headache. Background Sustained reductions in cluster headache burden after limited quantities of psilocybin‐containing mushrooms are anecdotally reported, although to date there are no controlled...

DOI: 10.1111/head.14420 (opens in new tab) Psilocybin Cluster headache Randomized controlled trial Anesthesia +4

Presentation and Short-term Course of New Onset Cannabis Induced Psychotic Disorder in Males

medRxiv January 31, 2022 Deepak Cyril D’souza, Justin Raj, Suhas Ganesh et al. preprint

Abstract Introduction Cannabis use has been associated with several psychosis outcomes including acute and persistent psychosis termed Cannabis Induced Psychotic Disorder (CIPD). The clinical and cognitive profile, course of CIPD, and the extent to which it is different from psychosis unrelated to cannabis exposure (PsyNoCan) is not clear. Methods The acute presentation and short-term (∼4...

DOI: 10.1101/2022.01.30.22270138 (opens in new tab) Full text (opens in new tab) Cannabis Psychosis Schizophrenia object-oriented programming Cognition +5

Grey Matter Volume Differences Associated with Extremely Low Levels of Cannabis Use in Adolescence

Journal of Neuroscience January 14, 2019 Catherine Orr, Philip A. Spechler, Zhipeng Cao et al. 100 citations

Rates of cannabis use among adolescents are high, and are increasing concurrent with changes in the legal status of marijuana and societal attitudes regarding its use. Recreational cannabis use is understudied, especially in the adolescent period when neural maturation may make users particularly vulnerable to the effects of Δ-9-tetrahydrocannabinol (THC) on brain structure. In the current...

Comparative and Interactive Human Psychopharmacologic Effects of Ketamine and Amphetamine

Archives of General Psychiatry September 1, 2005 John H. Krystal, Edward Perry, Ralitza Gueorguieva et al. 323 citations

BACKGROUND: In healthy individuals, ketamine hydrochloride and amphetamine sulfate produce cognitive, behavioral, and subjective effects resembling endogenous psychoses. Studying the comparative and interactive effects of these agents may provide insights into the roles of the glutamate and monoamine systems in psychosis and cognition. OBJECTIVES: To directly compare the effects of ketamine and...

Cannabinoid ‘model’ psychosis, dopamine–cannabinoid interactions and implications for schizophrenia

Cambridge University Press eBooks May 27, 2004 Deepak Cyril D’souza, Hyun Sang Cho, Edward Belk Perry et al. 32 citations

Hypotheses relating to the association between cannabis and psychosis may be divided into two groups. The exogenous hypothesis, which has received far greater attention, suggests that the consumption of cannabinoid compounds produces psychotic disorders by mechanisms that are extrinsic to the pathophysiology of naturally occurring psychoses. As discussed elsewhere in this book, converging...

Genomic Variation Predicts Real-Time Δ 9 -tetrahydrocannabinol Response in Humans

Uri Bright, Suhas Ganesh, Daniel F. Levey et al.

Abstract Background Cannabis is one of the most widely used psychoactive substances worldwide. Δ 9 -tetrahydrocannabinol (Δ 9 -THC) is the main contributor to cannabis-induced effects such as euphoria, anxiety, and psychotomimetic effects, and is metabolized by several hepatic enzymes, including CYP3A4. There are interindividual differences in how cannabis affects users, which have substantial...